Stockhead on MSN

Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Study finds no evidence that prostate cancer drugs interact with anticoagulants to increase bleeding, clotting risks

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
News-Medical.Net on MSN

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

European Commission approves AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

Telix Pharma jumps on positive Phase 3 prostate cancer trial results

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.
CURE

FDA Approves Pylarify TruVu to Expand Prostate Cancer Imaging

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Targeted Oncology

FDA OKs New Piflufolastat F 18 Formulation for Prostate Cancer Imaging

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
BioSpace

Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
The Manila Times

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Canc…

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Prostate cancer survivor urges men 'to act fast and stay alive'

Having survived the cancer which took his father, Graham Heron, from Bovington, is urging more men to act quickly to avoid falling victim to the most common cancer affecting men in the UK.
Medical Dialogues

Oxybutynin Reduces Hot Flashes in Men Receiving Androgen Deprivation Therapy for prostate cancer: Study

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...